UNSPSC 51141501: Acetazolamide

This classification denotes a diuretic and carbonic anhydrase inhibitor with the molecular formula C4H6N4O3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O3FX965V0I, chemically known as 1,3,4-thiadiazole-2-sulfonamide, 5-acetamido- but generally known as acetazolamide, which bears US NIH Compound Identifier 1986. Acetazolamide comes in many forms, including adipate ethyl ester, methyl, sodium, and tri-methyl.

UNSPSC 51141501 Acetazolamide is a Commodity code that nominally identifies a specific pharmaceutical product, but recent state and local procurement activity under this code does not reflect acetazolamide purchases. Instead, issuing bodies are soliciting naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription program services. The mismatch between the code's nominal scope and actual procurement activity suggests this code does not reliably capture pharmaceutical purchasing across state and local jurisdictions. State-level health agencies, county health departments, and multistate cooperative purchasing alliances are the primary issuing bodies using pharmaceutical-related codes, though the specific commodity designation here shows minimal aligned recent activity.

Recent opportunities posted include Seminole County, Florida's IFB60459723LAS (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (due April 3, 2026) soliciting vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance's S1070000015802 (due March 26, 2026) requesting generic pharmaceuticals and OTC products through three authorized wholesalers with awards effective July 1, 2026. Geographic activity spans Florida, Texas, and Minnesota with multistate participation, though the narrow pharmaceutical focus and code mismatch signal this Commodity code warrants verification before committing business development resources.